Avalo Therapeutics, Inc. (NASDAQ: AVTX) is a Healthcare company (Biotechnology) with a market capitalization of $414M. The Maz Rating grades it against the other companies in its sector.
About three months ago (July 2, 2026), Avalo Therapeutics, Inc. had a Maz Rating of 1.89 out of 5 (D, Sell), ranked against the other companies in its sector. Its strongest factor then was Momentum (3.92), above most of its sector; its weakest was Profitability (1.07), among the weakest in its sector. The other factors: Financial Health 2.92 (around the middle of its sector); Valuation 1.95 (more expensive than most of its sector); Growth 1.52 (below most of its sector). The current rating is for members: log in to see it.
At $7.16, Avalo Therapeutics, Inc. trades at 6466.4x sales and 0.9x book value. Over the last twelve months it generated about $64025 of revenue and a net loss of $168M. It runs a gross margin of 71.2%, an operating margin of -161961.0% and a net margin of -150259.3%. It shows return on equity of -34.2%, return on invested capital of -20.9% and a free cash flow yield of -15.9%. On the balance sheet: a debt-to-equity ratio of 0.00 and a current ratio of 16.63. Over the past 52 weeks the share price ranged from $6.53 to $24.27, with a beta of 0.74.
Avalo Therapeutics, Inc. does not currently pay a dividend.
10 Wall Street analyst ratings cover the stock: 6 Buy, 3 Hold and 1 Sell, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.